Structural changes involving tissue remodelling and fibrosis are major features of many
pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD) and …

In the lungs, fibrosis is a growing clinical problem that results in shortness of breath and can
end up in respiratory failure. Even though the main fibrotic disease affecting the lung is …

Goblet cell metaplasia, a disabling hallmark of chronic lung disease, lacks curative
treatments at present. To identify novel therapeutic targets for goblet cell metaplasia, we …

In asthma, goblet cell numbers are increased within the airway epithelium, perpetuating the
production of mucus that is more difficult to clear and results in airway mucus plugging …

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the
United States and is primarily caused by cigarette smoking. Increased numbers of mucus …

Since December 2019, a pandemic of COVID-19 disease, caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly spread across the globe. At …

Background Glucocorticoids act on the glucocorticoid receptor (GR; NR3C1) to resolve
inflammation and, as inhaled corticosteroids (ICS), are the cornerstone of treatment for …

Goblet cell metaplasia and mucus hypersecretion are observed in many pulmonary
diseases, including asthma, chronic obstructive pulmonary disease (COPD), and cystic …

Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease
characterized by incompletely reversible airflow limitation and seriously threatens the health …

Chronic obstructive pulmonary disease (COPD) is a progressive and devastating chronic
lung condition that has a significant global burden, both medically and financially. Currently …